MOTIE Innovation Designation Opens Direct Procurement Path for AVIEW LCS
Coreline Soft's lung cancer screening software, AVIEW LCS, has been designated an Excellent R&D Innovation Product by South Korea's Ministry of Trade, Industry and Energy (MOTIE). The three-year designation grants streamlined access to policy-based procurement channels, including negotiated public contracts, pilot purchasing via the Public Procurement Service, and export-linked government programs. (Image: AVIEW LCS, courtesy of Coreline Soft.)
- MOTIE innovation designation grants streamlined access to negotiated public procurement contracts
- Expanding B2G revenue visibility through national screening and public healthcare channels
- Policy-driven growth strategy spanning domestic public procurement and global expansion
Why this matters for government buyers
The designation allows contracting authorities to use negotiated contracts without standard competitive bidding for AVIEW LCS, reducing time to deployment. It also provides a clearer purchase pathway for agencies running national screening, public hospital modernization, or AI infrastructure programs. The result: faster implementation, clearer budgets, and a lower risk profile for large-scale screening use cases.
What the MOTIE designation includes
Administered by MOTIE, the Excellent R&D Innovation Product program validates outcomes of government-funded projects that show technical novelty and public-sector applicability. Selected products are prioritized for policy-based procurement and pilot purchases, linking R&D results directly to commercialization in public settings. For buyers, it signals a solution that has passed a higher bar for utility, scalability, and on-site use.
Learn more about the policy framework at MOTIE and the pilot purchasing process at the Public Procurement Service.
About AVIEW LCS
AVIEW LCS is AI-driven software that assists in determining the malignancy of pulmonary nodules detected in chest CT images. Built for low-dose CT workflows, it supports early detection and is suited to high-volume screening environments. Coreline Soft has built public-sector references through national screening programs, digital transformation projects in public hospitals, and government-linked R&D deployments, including AI-based chest diagnostic infrastructure projects that validated operational efficiency in real screening settings.
From one-off projects to sustained public demand
Industry observers see this as a shift from ad-hoc projects to a repeatable model that can generate recurring procurement demand. Public healthcare programs typically expand gradually after initial adoption and run on long cycles, which fits medium- to long-term revenue and ongoing support. With the designation, AVIEW LCS can be procured across central ministries, local governments, and public medical institutions, giving agencies a clearer path to scale.
Global traction supports policy-driven growth
Outside Korea, Coreline Soft has supplied AI solutions to European lung cancer screening initiatives, including the 4ITLR project, Germany's HANSE program, Italy's RISP initiative, and France's IMPULSION project. In Germany and other markets, the company has taken part in discussions and pilots where quantitative AI analysis is increasingly recommended as part of first-line screening workflows. This international footing strengthens the case for broader public-sector adoption.
What agencies can do next
- Use the negotiated contract route enabled by the MOTIE designation to reduce procurement timelines.
- Engage through PPS pilot purchasing for phased deployment and real-world validation within your network.
- Plan for integration with low-dose CT screening workflows and public hospital IT environments.
Bottom line
AVIEW LCS has moved into a policy-backed adoption phase with a clear procurement pathway and growing clinical references. For government buyers, this reduces friction-from evaluation to contract-while supporting scalable, screening-focused deployments across public healthcare systems.
Your membership also unlocks:
